TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:eLife
Main Authors: Palit, Sander AL, Vis, Daniel, Stelloo, Suzan, Lieftink, Cor, Prekovic, Stefan, Bekers, Elise, Hofland, Ingrid, Šuštić, Tonći, Wolters, Liesanne, Beijersbergen, Roderick, Bergman, Andries M, Győrffy, Balázs, Wessels, Lodewyk FA, Zwart, Wilbert, van der Heijden, Michiel S
Format: Artigo
Jezik:Inglês
Izdano: eLife Sciences Publications, Ltd 2019
Teme:
Cancer Biology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6968917/
https://ncbi.nlm.nih.gov/pubmed/31855178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.47430
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki